3 stories mentioning SHE:000623Updated 8d ago
Every FINWIRES story that references SHE:000623, newest first.
China's drug regulator approved Jilin Aodong Pharmaceutical (SHE:000623) subsidiary Jilin Aodong Pharmaceutical Group Yanji's levocarnitine injection.The drug addresses complications caused by secondary carnitine deficiency in hemodialysis patients with chronic kidney failure, according to a Tuesday filing with the Shenzhen bourse.
Jilin Aodong Pharmaceutical (SHE:000623) unit Yanji Pharmaceutical obtained the approval of China's medical products regulator for its supplemental application for diltiazem hydrochloride injection.The drug is indicated for supraventricular tachycardia, hypertensive emergencies and unstable angina, according to a Thursday filing with the Shenzhen bourse.The approval permits changes to formulation, production processes, quality standards and packaging.Shares of the company were down 1% Thursday.
Jilin Aodong Pharmaceutical's (SHE:000623) attributable profit rose 54% to 2.40 billion yuan in 2025 from 1.55 billion yuan in 2024, according to a Saturday filing with the Shenzhen bourse.Earnings per share at the Chinese drug company increased 44% to 2.0416 yuan from 1.3179 yuan in the previous year.Operating income declined 11% year over year to 2.34 billion yuan from 2.61 billion yuan.Shares decreased 1% during the midday break on Monday.
